Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma

Cancer

Volumn 85, Issue 12, 1999, Pages 2541-2548

  Nehls, Oliver ^a   Klump, Bodo ^a   Holzmann, Karlheinz ^a   Lammering, Guido ^b   Borchard, Franz ^c   Gruenagel, Hans Helmut ^d   Gaco, Vera ^a   Gregor, Michael ^a   Porschen, Rainer ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Aschaffenburg Hospital   (Germany)

^d Evangelic Hospital   (Germany)

Author keywords

p53; Preoperative radiotherapy; Prognosis; Rectal carcinoma

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM BIOPSY; RECTUM CARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECTAL NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033564784     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990615)85:12<2541::AID-CNCR8>3.0.CO;2-X     Document Type: Article

References (53)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Karanjia ND, Schache DJ, North WR, Heald RJ. 'Close shave' in anterior resection. Br J Surg 1990;277:510-2.
3. Hurst PA, Prout WG, Kelly JM, Bannister JJ, Walker RT. Local recurrence after low anterior resection using the staple gun. Br J Surg 1982;69:275-6.
4. Abulafi AM, Williams SN. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg 1994;81:7-9.
5. Gérard A, Buyse M, Nordlinger B, Loygue B, Pène F, Kempf P, et al. Preoperative radiotherapy as adjuvant therapy in rectal cancer. Ann Surg 1988;208:606-14.
6. Cedermark B, Johansson H, Rutqvist LE, Wilking N. Stockholm Colorectal Cancer Study Group. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Cancer 1995;75: 2269-75.
7. Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet 1996;348:1605-10.
8. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-97.
9. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high risk rectal carcinoma. N Engl J Med 1991;324:709-15.
10. Gastrointestinal Tumor Study Group. Prolongation of disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465-72.
11. Glimelius B, Isacsson U, Jung B, Påhlman L. Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favoring preoperative treatment. Int J Radiat Oncol Biol Phys 1997;2:281-7.
12. Lowe SW, Ruley E, Jacks T, Housman DE. P53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
13. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia teleangiectasia. Cell 1992;71:587-97.
14. Levine AJ, Momand J, Finlay CA. The tumor suppressor gene. Nature 1991;351:453-6.
15. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 mutations in colorectal carcinomas. Science 1989;244:217-21.
16. Lane DP. P53, guardian of the genome. Nature 1992;358: 15-6.
17. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. P53 is required for radiation induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
18. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996;2:1665-71.
19. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, et al. The role of p53 in spontaneous and radiation induced apoptosis in the gastrointestinal tract of normal and p53-deflcient mice. Cancer Res 1994;54:614-7.
20. Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993;53:4164-8.
21. Hendry JH, Cai WB, Roberts SA, Potten CS. P53 deficiency sensitizes cells to irradiation in the large but not the small intestine. Radiat Res 1997;148:254-9.
22. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, et al. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996;122:360-5.
23. Lane DP, Benchimol S. P53: oncogene or antioncogene? Genes Dev 1990;4:1-8.
24. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
25. Baas IO, Van den Berg FM, Mulder JWR, Clement MJ, Slebos RJC, Hamilton SR, et al. Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J Pathol 1996;178: 264-7.
26. Sobin LH, Wittekind C. TNM classification of malignant tumours. UICC, International Union Against Cancer, 5th ed. New York: Wiley-Liss, Inc., 1997.
27. Jass JR, Sobin LH. Histological typing of intestinal tumours. International histological classification of tumours. Geneva: World Health Organization, 2nd ed. Berlin: Springer-Verlag, 1989.
28. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992;151:237-44.
29. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1959;53:457-81.
30. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. P53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-23.
31. Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76:720-6.
32. Poller DN, Baxter KJ, Shepherd NA. P53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 1997;75:87-93.
33. Spitz FR, Giacco GG, Hess K, Larry L, Rich TA, Janjan N, et al. P53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res 1997;3:1685-90.
34. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, et al. Ki-ras mutation and p53 overexpression predict the clinical behaviour of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998;58:1149-58.
35. Hall PA, Lane DP. P53 in tumour pathology: can we trust immunohistochemistry? - revisited! J Pathol 1994;172:1-4.
36. Dix B, Robbins P, Carrello S, House A, Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 1994;70:585-90.
37. Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal carcinomas. Br J Cancer 1996;74:216-23.
38. Greenblatt MS, Bennett WP, Hollstein, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54: 4855-78.
39. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemlstry? J Pathol 1992;166:329-30.
40. Lee JM, Bernstein A. P53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993;90:5742-6.
41. Xia F, Wang X, Wang YH, Tsang NM, Yandell DW, Kelsey KT, et al. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 1995; 55:12-5.
42. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. P53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993;53:3667-9.
43. Desai GR, Myerson RJ, Higashikubo R, Birnbaum E, Fleshman J, Fry R, et al. Carcinoma of the rectum. Possible cellular predictors of metastatic potential and response to radiotherapy. Dis Colon Rectum 1996;39:1090-6.
44. Nakano T, Oka K, Taniguchi N. Manganese superoxide dismutase expression correlates with p53 status and local recurrence of cervical carcinoma treated with radiation therapy. Cancer Res 1996;56:2771-5.
45. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, et al. P53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89:158-65.
46. Awwad S, Jaros E, Somes J, Lunec J. P53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys 1996;34:323-32.
47. Kokoska MS, Piccirillo JF, El-Mofty SK, Emami B, Haughey BH, Scholnick SB. Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy. Cancer 1996;78:1693-700.
48. Bracey TS, Miller JC, Preece A, Paraskeva C. γ-Radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in absence of wild-type p53. Oncogene 1995;10:2391-6.
49. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 1998;58: 1793-7.
50. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381:713-6.
51. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
52. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-18.
53. Horn A, Morild I, Dahl O. Tumour shrinkage and downstaging after preoperative radiation of rectal adenocarcinomas. Radiother Oncol 1990;18:19-28.